Spark Biomedical Announces First-in-Human Clinical Trial Results for 'Neuro-Hemostat,' a Device that Uses Auricular Nerve Stimulation to Aid in Hemostasis
A New Horizon in Bioelectronic Medicine
Researchers from Northwell Health's Feinstein Institutes for Medical Research and Spark Biomedical, a medical device venture, have announced the results of their first-in-human clinical trial using transcutaneous auricular neurostimulation (tAN) technology. This study presents an innovative approach to regulating the body's hemostasis mechanisms through bioelectronic signals, rather than traditional physical compression or chemical hemostatic agents. By stimulating nerves in the ear, the researchers demonstrated the ability to activate blood coagulation responses, advancing the clinical utility of bioelectronic medicine.
Hemostasis Mechanism Through Vagus and Trigeminal Nerve Stimulation
The study evaluated the use of a non-invasive device worn on the ear to simultaneously or individually stimulate the vagus nerve and trigeminal nerve. The clinical results revealed that this electrical stimulation helps to prime platelets, which play a crucial role in the hemostasis process, enabling them to respond immediately when an injury occurs. In particular, transcutaneous auricular vagus nerve stimulation (taVNS) showed excellent efficacy in promoting all stages of blood coagulation: initiation, propagation, and stabilization.
Potential to Transform Trauma and Emergency Medical Care
This technology has the potential to be a game-changer in various emergency situations, including traumatic hemorrhage in combat, surgical bleeding, and postpartum hemorrhage. Traditional tourniquets can only be used on limbs, but the wearable ear stimulation device can induce a systemic coagulation response, making it applicable to bleeding in the torso or organs. It is also expected to be useful in managing chronic bleeding risks in patients with inherited bleeding disorders such as hemophilia and von Willebrand disease.
Commercialization Strategy and Growth Potential of the Hemostasis Control Market
Spark Biomedical has established a dedicated business unit, Five Liters, to commercialize this hemostasis technology and has begun full-scale development. The global hemostasis and hemorrhage control market is estimated at $3.5 billion to $4.5 billion in 2025 and is projected to grow steadily to $6 billion by 2035. Five Liters has a strategic advantage in that it is based on the company's existing nerve stimulation platform, which has already received FDA approval, allowing it to significantly shorten the regulatory approval and market entry period.
Future Challenges and Prospects for Regulatory Approval
However, this clinical study is an early-stage feasibility study conducted on healthy adults, so a large-scale clinical trial on actual patients is essential. A key to future FDA approval will be to thoroughly verify that bioelectronic stimulation does not cause adverse effects such as systemic hypercoagulability or thrombosis. If safety and efficacy are ultimately demonstrated, it has the potential to revolutionize the medical market as a new, non-invasive digital therapeutic with no risk of drug side effects.
The neuro-hemostat technology, jointly developed by Spark Biomedical and the Feinstein Institutes, is a disruptive innovation that could shake up the global hemostasis control market, which is estimated at $3.5 billion to $4.5 billion in 2025. By successfully securing platelet activation data in the first-in-human mechanistic trial, it has established a research milestone, expanding the application of bioelectronic medicine from chronic diseases to emergency medicine and hemostasis. In the short term, it is expected to pursue a rapid regulatory approval pathway through its dedicated business unit, Five Liters, based on existing FDA-approved devices. In the medium to long term, it aims to replace the existing treatment standards centered on chemical hemostatic agents and limb compression tourniquets, and to capture a $6 billion market by 2035 with a diversified pipeline, including surgical bleeding and hemophilia patient care.